Novartis raises profit forecast on demand for new drugs

The drugmaker kept its overall sales forecast unchanged

Novartis shares fell as much as much as 3.1% in early trading in Zurich.

Sales of Novartis’ closely-watched prostate cancer drug Pluvicto disappointed in the latest quarter, taking the shine off a raised profit forecast from the Swiss pharma company.

Novartis shares fell as much as much as 3.1% in early trading in Zurich, trimming this year’s gain to 14%, after sales of the treatment fell short of analysts’ estimates.